A number of epinephrine auto-injector manufacturers have released statements in recent days addressing supply issues related to the anaphylaxis treatment.
In May, the Food and Drug Administration posted a drug shortage alert, adding Mylan’s EpiPen (epinephrine injection) to the drug shortage list. Mylan released a statement last week expressing that they are continuing to experience ‘interruptions in the production’ of EpiPen 0.3mg and EpiPen Jr 0.15mg Auto-Injectors.
EpiPen is manufactured by Meridian, a subsidiary of Pfizer, and Mylan said that they are actively exploring several options to help stabilize the supply. In their own statement, Pfizer confirmed that they cannot guarantee that the product will be available at all pharmacies. They also urged patients to be prudent about refilling prescriptions for EpiPen if they already have supplies of unexpired product readily available, to help ensure other patients have access to the medication.
Kaléo, the manufacturer of the epinephrine auto-injector, AUVI-Q, reports that they have sufficient supply to meet ‘any anticipated demand’. The Company released a statement affirming the product’s availability. “Kaléo is able to fill, and is filling, all the AUVI-Q orders through our Direct Delivery service at www.auvi-q.com,” said Phil Rackliffe, General Manager of Allergy and Pediatrics, at Kaléo. “It’s important to note that patients must obtain AUVI-Q through the Direct Delivery service to ensure delivery to their home or healthcare provider’s office and the best expiration dating for AUVI-Q.” AUVI-Q includes a voice instruction feature to guide a user through administration and is available in 0.1mg, 0.15mg, and 0.3mg strength auto-injectors.
This article originally appeared on MPR